V. REFERENCES 



82. Morris, J.E.; Price, J.M.; Lalich, J.J.; Stein, 

 R.J. (1969) The carcinogenic activity of some 5- 

 nitrofuran derivatives in the rat. Cancer Res. 

 29:2145-2156. 



83. Murphy, E.D. (1972) Hyperplastic and early 

 neoplastic changes in the ovaries of mice after 

 genie deletion of germ cells. J. Natl Cancer 

 Inst. 48:1283- 1291. 



84. Murphy, E.D ; Reamer, W.G. (1973) Plasma 

 gonadotropin levels during early stages of ovari 

 an tumorigenesis in mice of the W'^IW" genotype. 

 Cancer Res. 33:721-723. 



85. Murphy, E.D.; Russell, E.S. (1963) Ovarian 

 tumorigenesis following genie deletion of germ 

 cells in hybrid mice. Acta Union Intl. Cancer 

 19:779-782 



86. Myhr. B , Bowers, L., Caspary, W J (1985) 

 Assays for the induction of gene mutations at 

 the thymidine kinase locus in L5178Y mouse 

 lymphoma cells in culture. Prog Mutat. Res 

 5:555-568. 



87. National Cancer Institute (NCI) (1976) 

 Guidelines for Carcinogen Bioassay in Small Ro- 

 dents. NCI Technical Report No 1 U.S. De 

 partment of Health, Education, and Welfare, 

 Public Health Service, National Institutes of 

 Health. 65 p. 



88. National Institute for Occupational Safety 

 and Health (NIOSH) (1983) Registry of To.xic Ef- 

 fects of Chemical Substances, Vol. 2. 



89. National Institutes of Health (NIH) (1978) 

 Open Formula Rat and Mouse Ration (NIH-07) 

 Specification NIH-11-1335. U.S. Department of 

 Health, Education, and Welfare, Public Health 

 Service, National Institutes of Health, Bethesda, 

 MD 



90. National Toxicology Program (NTP) (1988) 

 Toxicology and Carcinogenesis Studies of Nitro- 

 furazone in F344/N Rats and B6C3Fi Mice. 

 NTP Technical Report No. 337. US. Depart- 

 ment of Health and Human Services, Public 

 Health Service, National Institutes of Health, 

 Research Triangle Park, NC. 183 p. 



91 NCI/SRI Mark II (1978) Data Base on Cate- 

 gory E Drug Exposure. National Cancer Insti- 

 tute, Contract No. NOl CP-33285. 



92. Nissim, J A (1957) Increased pituitary go- 

 nadotropin activity after degeneration of semi- 

 niferous tubules produced by nitrofurazone. 

 Lancet 1:304-305. 



93. Olivard, J.; Valenti, S.; Buzard, J A. (1962) 

 The metabolism of 5-nitro-2 furaldehyde acetyl- 

 hydrazone. J. Med. Pharm. Chem 5:524-531. 



94. Olivard, J ; Rose, G.M.; Klein, G.M.; Ileotis, 

 J. P. (1976) Metabolic and photochemical hy- 

 droxylation of 5-nitro-furancarboxaldehyde de- 

 rivatives. .] Med Chem 19:729:731 



95. Olive. P K. (1979a) Inhibition of DNA syn- 

 thesis by nilroheterocycles. 1. Correlation with 

 half-wave reduction potential, Br. J. Cancer 

 40:89-93. 



96. Olive, PL. (1979b) Inhibition of DNA syn- 

 thesis by nitroheterocycles. II. Mechanisms of 

 cytotoxicity. Br. J. Cancer 40:94-104. 



97. Olive, PL. (1980) Mechanisms of the m uitro 

 toxicity of nitroheterocycles, including F'lagyl 

 and misonidazole. Conference Proceedings: Ra- 

 diation Sensitizers-Their Use in Clinical Man- 

 agement of Cancer, pp 39-44. 



98. Olive, PL. (1981) Correlation between the 

 half-wave reduction potentials of nitrohetero- 

 cycles and their mutagenicity in Chinese ham- 

 ster V79 spheroids. Mutat. Res. 82:137-145. 



99. Olive, P.L.; McCalla, DR. (1977) Cytotoxic- 

 ity and DNA damage to mammalian cells by ni- 

 trofurans. Chem. Biol. Interact. 16:223-233. 



100. Paul, HE ; Paul, M F (1964) Experimental 

 Chemotherapy, Vol. II New York: Academic 

 Press, p. 307. 



101 Paul, HE; Ells, U.R.; Kopko, F.; Bender, 

 R.C. (1960) Metabolic degradation of the nitro- 

 furans. J. Med. Pharm. Chem. 2:563-584. 



Nitrofurantoin, NTP TR 341 



72 



